Adult Coats' Disease Successfully Managed With The Dexamethasone Intravitreal Implant (Ozurdex (R)) Combined With Retinal Photocoagulation

Purpose: To report a case of Coats' disease managed with the dexamethasone intravitreal implant Ozurdex (R) (Allergan, Inc., Irvine, Calif., USA) combined with retinal photocoagulation.Methods: A 46-year-old female with 20/200 visual acuity was diagnosed with Coats' disease with secondary retinal vasoproliferative tumor. An initial approach was performed with an intravitreal injection of the sustained-release dexamethasone implant Ozurdex. After reattachment of the retina, the telangiectatic vessels were treated with laser photocoagulation.Results: The patient's visual acuity improved to 20/25 after the intravitreal Ozurdex. No further recurrences of exudation were evident through the 12-month follow-up.Conclusions: Ozurdex may be an effective initial therapeutic approach for Coats' disease with immediate anatomical response and visual improvement.